ROCKVILLE, Md.--(BUSINESS WIRE)--MEDIPOST America Inc. (CEO: Dr. Antonio Lee) today announced the US FDA approval of Phase 1/2 clinical trial for PNEUMOSTEM®. The Phase 1/2 trial will assess the safety and efficacy of PNEUMOSTEM® on prematurely born infants who will be at high-risk of developing Bronchopulmonary Dysplasia (BPD). PNEUMOSTEM® is made from allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cells (hUCB-MSCs), and is expected to have effect on regenerating the lung tissue and improving inflammatory responses in premature infants.
Help employers find you! Check out all the jobs and post your resume.
